Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: An intriguing clinical observation

被引：0

作者：

Merimsky, O ^{[1
]}

机构：

[1] Tel Aviv Univ, Sackler Sch Med, Tel Aviv Sourasky Med Ctr, Div Oncol,Unit Bone & Soft Tissue Oncol, IL-64239 Tel Aviv, Israel

来源：

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE | 2004年 / 14卷 / 05期

关键词：

leiomyosarcoma; rapamycin; gemcitabine;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The emerging anti-cancer approach is based on combining a 'traditional' cytotoxic drug with a 'signaling' blocking agent. Such combination, if designed and applied properly, may increase selectivity towards tumor cells. The use of such combinations requires smart planning and choice of the drugs to be combined, their proper dosing as well as correct sequence and schedule of application. The combination of the anti-metabolite gemcitabine and the mTOR blocker, rapamycin, has achieved an impressive response in a patient with metastatic leiomyosarcoma.

引用

页码：931 / 935

页数：5

共 17 条

[1] Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer [J].

Bruns, CJ ;

Koehl, GE ;

Guba, M ;

Yezhelyev, M ;

Steinbauer, M ;

Seeliger, H ;

Schwend, A ;

Hoehn, A ;

Jauch, KW ;

Geissler, EK .

CLINICAL CANCER RESEARCH, 2004, 10 (06) :2109-2119

[2]

Chen J, 2003, CURR TOP MICROBIOL, V279, P245

[3] IDENTIFICATION OF AN 11-KDA FKBP12-RAPAMYCIN-BINDING DOMAIN WITHIN THE 289-KDA FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN AND CHARACTERIZATION OF A CRITICAL SERINE RESIDUE [J].

CHEN, J ;

ZHENG, XF ;

BROWN, EJ ;

SCHREIBER, SL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (11) :4947-4951

[4] Clinical development of mammalian target of rapamycin inhibitors [J].

Dancey, JE .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2002, 16 (05) :1101-+

[5] The evolving role of sirolimus in renal transplantation [J].

Dupont, P ;

Warrens, AN .

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2003, 96 (06) :401-409

[6] Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor [J].

Guba, M ;

von Breitenbuch, P ;

Steinbauer, M ;

Koehl, G ;

Flegel, S ;

Hornung, M ;

Bruns, CJ ;

Zuelke, C ;

Farkas, S ;

Anthuber, M ;

Jauch, KW ;

Geissler, EK .

NATURE MEDICINE, 2002, 8 (02) :128-135

[7] Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial [J].

Hensley, ML ;

Maki, R ;

Venkatraman, E ;

Geller, G ;

Lovegren, M ;

Aghajanian, C ;

Sabbatini, P ;

Tong, W ;

Barakat, R ;

Spriggs, DR .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) :2824-2831

[8]

Hosoi H, 1999, CANCER RES, V59, P886

[9] Rapamycins - Mechanism of action and cellular resistance [J].

Huang, SL ;

Bjornsti, MA ;

Houghton, PJ .

CANCER BIOLOGY & THERAPY, 2003, 2 (03) :222-232

[10] PIK-RELATED KINASES - DNA-REPAIR, RECOMBINATION, AND CELL-CYCLE CHECKPOINTS [J].

KEITH, CT ;

SCHREIBER, SL .

SCIENCE, 1995, 270 (5233) :50-51

← 1 2 →